Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells

BACKGROUND AND PURPOSE: Around 40–50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Nanomedicine
Autors principals: Falgàs, Aïda, Pallarès, Victor, Unzueta, Ugutz, Núñez, Yáiza, Sierra, Jorge, Gallardo, Alberto, Alba-Castellón, Lorena, Mangues, Maria Antonia, Álamo, Patricia, Villaverde, Antonio, Vázquez, Esther, Mangues, Ramon, Casanova, Isolda
Format: Artigo
Idioma:Inglês
Publicat: Dove 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944372/
https://ncbi.nlm.nih.gov/pubmed/33716502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S289733
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars